Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sm Faysal Bellah, Md. Abdus Salam, S. M. Saker Billah & Md Rezaul Karim. (2023) Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer. Annals of Human Biology 50:1, pages 63-75.
Read now
Read now
Larry House, Michael J. Seminerio, Snezana Mirkov, Jacqueline Ramirez, Maxwell Skor, Joseph R. Sachleben, Masis Isikbay, Hari Singhal, Geoffrey L. Greene, Donald Vander Griend, Suzanne D. Conzen & Mark J. Ratain. (2018) Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 48:10, pages 973-983.
Read now
Read now
Yohei Kosugi & Junzo Takahashi. (2015) Species differences and substrate specificity of CYP3A heteroactivation by efavirenz. Xenobiotica 45:4, pages 345-352.
Read now
Read now
Dennis Rokitta, Kay Pfeiffer, Christina Streich, Henrik Gerwin & Uwe Fuhr. (2013) The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro. Toxicology Mechanisms and Methods 23:8, pages 576-583.
Read now
Read now
Helen E. Cubitt, Karen R. Yeo, Eleanor M. Howgate, Amin Rostami-Hodjegan & Zoe E. Barter. (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:8, pages 623-638.
Read now
Read now
Hege Christensen, Anette L. Hestad, Espen Molden & Liv Mathiesen. (2011) CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Xenobiotica 41:1, pages 1-5.
Read now
Read now
C. Emoto, H. Nishida, H. Hirai & K. Iwasaki. (2007) CYP3A4 and CYP3A5 catalyse the conversion of the -methyl-D-aspartate (NMDA) antagonist CJ-036878 to two novel dimers. Xenobiotica 37:12, pages 1408-1420.
Read now
Read now
C. Emoto & K. Iwasaki. (2007) Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: The effect of the expression of cytochrome 5 with recombinant P450 enzymes. Xenobiotica 37:9, pages 986-999.
Read now
Read now
C. Emoto & K. Iwasaki. (2007) Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation. Xenobiotica 37:6, pages 592-603.
Read now
Read now
Articles from other publishers (27)
Edward Zheng, Paulina Madura, Jakub Grandos, Marlena Broncel, Agnieszka Pawlos, Ewelina Woźniak & Paulina Gorzelak-Pabiś. (2024) When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomedicine & Pharmacotherapy 170, pages 115966.
Crossref
Crossref
QingLiang Wu, YiTing Hu, CuiTong Wang, Wei Wei, LanLan Gui, WuShuang Zeng, Changxiao Liu, Wei Jia, Jia Miao & Ke Lan. (2022) Reevaluate In Vitro CYP3A Index Reactions of Benzodiazepines and Steroids between Humans and Dogs. Drug Metabolism and Disposition 50:6, pages 741-749.
Crossref
Crossref
Houcemeddine Othman, Jorge E. B. da Rocha & Scott Hazelhurst. (2021) Single Nucleotide Polymorphism Induces Divergent Dynamic Patterns in CYP3A5: A Microsecond Scale Biomolecular Simulation of Variants Identified in Sub-Saharan African Populations. International Journal of Molecular Sciences 22:15, pages 7786.
Crossref
Crossref
Yilue Zhang, Thankhoe A. Rants'o, Da Jung, Elizabeth Lopez, Kodye Abbott, Satyanarayana R. Pondugula, Lane McLendon, Jingjing Qian, Richard A. Hansen & Angela I. Calderón. (2019) Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of açaí and maca. Phytomedicine 59, pages 152915.
Crossref
Crossref
Zi-Ru Dai, Jing Ning, Gui-Bo Sun, Ping Wang, Feng Zhang, Hong-Ying Ma, Li-Wei Zou, Jie Hou, Jing-Jing Wu, Guang-Bo Ge, Xiao-Bo Sun & Ling Yang. (2019) Cytochrome P450 3A Enzymes Are Key Contributors for Hepatic Metabolism of Bufotalin, a Natural Constitute in Chinese Medicine Chansu. Frontiers in Pharmacology 10.
Crossref
Crossref
Kang Xiao, Jie Gao, Shi-Jia Weng, Yan Fang, Na Gao, Qiang Wen, Han Jin & Hai-Ling Qiao. (2018) CYP3A4/5 Activity Probed with Testosterone and Midazolam: Correlation between Two Substrates at the Microsomal and Enzyme Levels. Molecular Pharmaceutics 16:1, pages 382-392.
Crossref
Crossref
Viktoriia Starokozhko, Mette Hemmingsen, Layla Larsen, Soumyaranjan Mohanty, Marjolijn Merema, Rodrigo C. Pimentel, Anders Wolff, Jenny Emnéus, Anders Aspegren, Geny Groothuis & Martin Dufva. (2018) Differentiation of human-induced pluripotent stem cell under flow conditions to mature hepatocytes for liver tissue engineering. Journal of Tissue Engineering and Regenerative Medicine 12:5, pages 1273-1284.
Crossref
Crossref
Myeongjin Yi, Sun-Ah Cho, Jungki Min, Dong Hyun Kim, Jae-Gook Shin & Su-Jun Lee. (2017) Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis. Archives of Biochemistry and Biophysics 620, pages 43-51.
Crossref
Crossref
Yuqing Xiong, Zhao Yuan, Jingzhi Yang, Chunhua Xia, Xinhua Li, Shibo Huang, Hong Zhang & Mingyi Liu. (2014) CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 41:2, pages 117-124.
Crossref
Crossref
Kazuo Oda, Katsuhiro Yamano & Yukio Otsuka. (2015)
In vitro-in vivo
extrapolations to evaluate the effect of concomitant drugs on tacrolimus (FK506) exposure
. Biopharmaceutics & Drug Disposition 36:5, pages 265-274.
Crossref
Crossref
Ilia G. Denisov, Yelena V. Grinkova, Javier L. Baylon, Emad Tajkhorshid & Stephen G. Sligar. (2015) Mechanism of Drug–Drug Interactions Mediated by Human Cytochrome P450 CYP3A4 Monomer. Biochemistry 54:13, pages 2227-2239.
Crossref
Crossref
Kazuo Oda & Katsuhiro Yamano. (2014) Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506). Biopharmaceutics & Drug Disposition 35:9, pages 501-512.
Crossref
Crossref
Nikunjkumar Patel, Sebastian Polak, Masoud Jamei, Amin Rostami-Hodjegan & David B. Turner. (2014) Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: A case study using the BCS/BDDCS Class II drug nifedipine. European Journal of Pharmaceutical Sciences 57, pages 240-249.
Crossref
Crossref
Y-P Zhang, X-C Zuo, Z-J Huang, J-J Cai, J Wen, D D Duan & H Yuan. (2013) CYP3A5 polymorphism, amlodipine and hypertension. Journal of Human Hypertension 28:3, pages 145-149.
Crossref
Crossref
Xiao-cong Zuo, Ya-nan Zhou, Bi-kui Zhang, Guo-ping Yang, Ze-neng Cheng, Hong Yuan, Dong-sheng Ouyang, Shi-kun Liu, Jeffrey S. Barrett, Pei-jiong Li, Zhi Liu, Hong-yi Tan, Ren Guo, Ling-yun Zhou, Yue-liang Xie, Zuo-jun Li, Jing Li, Chun-jiang Wang & Jiang-lin Wang. (2013) Effect of CYP3A5*3 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine. Drug Metabolism and Pharmacokinetics 28:5, pages 398-405.
Crossref
Crossref
Yanhui Lu, Craig W. Hendrix & Namandjé N. Bumpus. (2012) Cytochrome P450 3A5 Plays a Prominent Role in the Oxidative Metabolism of the Anti-Human Immunodeficiency Virus Drug Maraviroc. Drug Metabolism and Disposition 40:12, pages 2221-2230.
Crossref
Crossref
K. Rowland Yeo, R.L. Walsky, M. Jamei, A. Rostami-Hodjegan & G.T. Tucker. (2011) Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover. European Journal of Pharmaceutical Sciences 43:3, pages 160-173.
Crossref
Crossref
Arden Barry & Marc Levine. (2010) A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients. Therapeutic Drug Monitoring 32:6, pages 708-714.
Crossref
Crossref
Shayne Cox GadMichael Oettel. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia.
Ilia G. Denisov, Daniel J. Frank & Stephen G. Sligar. (2009) Cooperative properties of cytochromes P450. Pharmacology & Therapeutics 124:2, pages 151-167.
Crossref
Crossref
D Tomalik-Scharte, D Lütjohann, O Doroshyenko, D Frank, A Jetter & U Fuhr. (2009) Plasma 4β-Hydroxycholesterol: An Endogenous CYP3A Metric?. Clinical Pharmacology & Therapeutics 86:2, pages 147-153.
Crossref
Crossref
Hege Christensen, Liv Mathiesen, Lillian W. Postvoll, Bjørn Winther & Espen Molden. (2009) Different Enzyme Kinetics of Midazolam in Recombinant CYP3A4 Microsomes from Human and Insect Sources. Drug Metabolism and Pharmacokinetics 24:3, pages 261-268.
Crossref
Crossref
Chandra Prakash, Weiwei Wang, Thomas O'Connell & Kim A. Johnson. (2008)
CYP2C8- and CYP3A-Mediated
C
-Demethylation of (3-{[(4-
tert
-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance
. Drug Metabolism and Disposition 36:10, pages 2093-2103.
Crossref
Crossref
Hei-Young Ku, Hee-Jeong Ahn, Kyung-Ah Seo, Hyunmi Kim, Minkyung Oh, Soo Kyung Bae, Jae-Gook Shin, Ji-Hong Shon & Kwang-Hyeon Liu. (2008) The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. Drug Metabolism and Disposition 36:6, pages 986-990.
Crossref
Crossref
Chen Chen, Yongsheng Chen, Joseph Pontillo, Zhiqiang Guo, Charles Q. Huang, Dongpei Wu, Ajay Madan, Takung Chen, Jenny Wen, Qiu Xie, Fabio C. Tucci, Martin Rowbottom, Yun-Fei Zhu, Warren Wade, John Saunders, Haig Bozigian & R. Scott Struthers. (2008) Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity. Bioorganic & Medicinal Chemistry Letters 18:11, pages 3301-3305.
Crossref
Crossref
Luigi Quintieri, Pietro Palatini, Alberto Nassi, Paolo Ruzza & Maura Floreani. (2008) Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochemical Pharmacology 75:6, pages 1426-1437.
Crossref
Crossref
F Josephson, A Allqvist, M Janabi, J Sayi, E Aklillu, M Jande, M Mahindi, J Burhenne, Y Bottiger, L L Gustafsson, W E Haefeli & L Bertilsson. (2007) CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir. Clinical Pharmacology & Therapeutics 81:5, pages 708-712.
Crossref
Crossref